Clinical trials search results

Alliance A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion Study to Alliance Study A011502
SWOG S1418: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
WONIX 2016-0608 (UW19071): Proton Density Water Fraction as an MR-Based Measurement of Breast Fibroglandular Tissue Volume and Percentage
A191901: Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions / Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
NRG-BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score
CCTG MA.39: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
CCTG MA.39
Alliance A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
UW19046: Pilot Study of FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)
NRG GY026

Contact us

To learn more about clinical trials at ProHealth Care, email research.institute@phci.org or call 262-928-3447.

Quick Access Links